ATE256195T1 - Cytopatische viren zur therapie und prophylaxe der neoplasie - Google Patents
Cytopatische viren zur therapie und prophylaxe der neoplasieInfo
- Publication number
- ATE256195T1 ATE256195T1 AT97951519T AT97951519T ATE256195T1 AT E256195 T1 ATE256195 T1 AT E256195T1 AT 97951519 T AT97951519 T AT 97951519T AT 97951519 T AT97951519 T AT 97951519T AT E256195 T1 ATE256195 T1 AT E256195T1
- Authority
- AT
- Austria
- Prior art keywords
- replication phenotype
- cells
- neoplastic cells
- viral
- neoplastic
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 4
- 230000010076 replication Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3461596P | 1996-12-31 | 1996-12-31 | |
| PCT/US1997/022036 WO1998029555A2 (en) | 1996-12-31 | 1997-12-10 | Cytopathic viruses for therapy and prophylaxis of neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE256195T1 true ATE256195T1 (de) | 2003-12-15 |
Family
ID=21877522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97951519T ATE256195T1 (de) | 1996-12-31 | 1997-12-10 | Cytopatische viren zur therapie und prophylaxe der neoplasie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6080578A (de) |
| EP (1) | EP0958371B1 (de) |
| JP (1) | JP4225577B2 (de) |
| AT (1) | ATE256195T1 (de) |
| AU (1) | AU723604B2 (de) |
| CA (1) | CA2273825C (de) |
| DE (1) | DE69726759T2 (de) |
| DK (1) | DK0958371T3 (de) |
| ES (1) | ES2212815T3 (de) |
| PT (1) | PT958371E (de) |
| WO (1) | WO1998029555A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6326356B1 (en) | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
| US20010006633A1 (en) * | 1998-05-15 | 2001-07-05 | David Kirn | Adenovirus-chemotherapeutic combination for treating cancer |
| US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| US6764674B1 (en) * | 1999-01-28 | 2004-07-20 | Onyx Pharmaceuticals Inc. | Adenovirus E1B shuttle vectors |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
| US6911200B2 (en) | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
| EP1320582A2 (de) * | 2000-08-03 | 2003-06-25 | Onyx Pharmaceuticals | Adenovirus e1b-55k einzelne aminosäuremutante und deren verwendungsmethode |
| US20040101825A1 (en) * | 2001-09-26 | 2004-05-27 | Van Meir Erwin G. | Viruses targeted to hypoxic cells and tissues |
| US7285414B2 (en) * | 2000-09-26 | 2007-10-23 | Emory University | Viruses targeted to hypoxic cells and tissues |
| US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| WO2003010306A1 (en) * | 2001-07-23 | 2003-02-06 | Onyx Pharmaceuticals, Inc. | Viral mutants that selectively replicate in targeted human cancer cells |
| WO2003029448A1 (en) * | 2001-09-29 | 2003-04-10 | Yun, Chae-Ok | Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| JP5213298B2 (ja) | 2002-05-27 | 2013-06-19 | ホルム，ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| US7364727B2 (en) | 2002-07-22 | 2008-04-29 | Cell Genesys, Inc. | Metastatic colon cancer specific promoter and uses thereof |
| AU2003287451A1 (en) | 2002-11-01 | 2004-06-07 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising ebv-specific promoter |
| US20040202663A1 (en) * | 2003-01-28 | 2004-10-14 | Shanghai Sunway Biotech Co., Ltd. | Therapy for primary and metastatic cancers |
| US20050036989A1 (en) * | 2003-07-18 | 2005-02-17 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
| CA2546178A1 (en) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | New use of adenovirus and nucleic acids coding therefor |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| WO2013116778A2 (en) | 2012-02-02 | 2013-08-08 | Board Of Regents | Immunogenic adenovirus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE178490T1 (de) * | 1993-02-16 | 1999-04-15 | Onyx Pharmaceuticals | Cytopathische viren zur therapie und prophylaxe der neoplasie |
| US5801029A (en) * | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
-
1997
- 1997-12-08 US US08/986,331 patent/US6080578A/en not_active Expired - Fee Related
- 1997-12-10 WO PCT/US1997/022036 patent/WO1998029555A2/en not_active Ceased
- 1997-12-10 EP EP97951519A patent/EP0958371B1/de not_active Expired - Lifetime
- 1997-12-10 ES ES97951519T patent/ES2212815T3/es not_active Expired - Lifetime
- 1997-12-10 AU AU55145/98A patent/AU723604B2/en not_active Ceased
- 1997-12-10 AT AT97951519T patent/ATE256195T1/de active
- 1997-12-10 JP JP53001898A patent/JP4225577B2/ja not_active Expired - Fee Related
- 1997-12-10 PT PT97951519T patent/PT958371E/pt unknown
- 1997-12-10 CA CA2273825A patent/CA2273825C/en not_active Expired - Fee Related
- 1997-12-10 DE DE1997626759 patent/DE69726759T2/de not_active Expired - Lifetime
- 1997-12-10 DK DK97951519T patent/DK0958371T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0958371A2 (de) | 1999-11-24 |
| AU5514598A (en) | 1998-07-31 |
| EP0958371B1 (de) | 2003-12-10 |
| WO1998029555A2 (en) | 1998-07-09 |
| JP2001508290A (ja) | 2001-06-26 |
| JP4225577B2 (ja) | 2009-02-18 |
| US6080578A (en) | 2000-06-27 |
| DE69726759T2 (de) | 2005-01-13 |
| CA2273825C (en) | 2011-02-08 |
| DK0958371T3 (da) | 2004-04-13 |
| CA2273825A1 (en) | 1998-07-09 |
| PT958371E (pt) | 2004-04-30 |
| ES2212815T3 (es) | 2004-08-01 |
| DE69726759D1 (de) | 2004-01-22 |
| AU723604B2 (en) | 2000-08-31 |
| WO1998029555A3 (en) | 1998-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE199568T1 (de) | Cytopatische viren zur therapie und prophylaxe der neoplasie | |
| ATE256195T1 (de) | Cytopatische viren zur therapie und prophylaxe der neoplasie | |
| ES8307500A1 (es) | "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante". | |
| AU3698697A (en) | Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament | |
| AU4306896A (en) | Method for the preparation of a viral vector by intermolecular homologous recombination | |
| CA2051289A1 (en) | Viral mediated destruction of neoplastic cells | |
| NO20020571L (no) | Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse | |
| DE69518840D1 (en) | N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren | |
| GR3024173T3 (en) | Assembled viral particles and their use in a vaccine to rotaviral disease. | |
| MXPA02007271A (es) | Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales. | |
| ATE272713T1 (de) | Ehv-1 vektoren | |
| NO943288L (no) | Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer | |
| NO951762L (no) | Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff | |
| AU5489500A (en) | Isolation of a human retrovirus | |
| AU698242B2 (en) | Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases | |
| DK0480391T3 (da) | Emulgatorfrie emulsionspolymerer, deres fremstilling og deres anvendelse i farmaceutiske præparater med forlænget frigivelse af virksomt stof | |
| Pluta et al. | Balance between Retroviral Latency and Transcription: Based on HIV Model. Pathogens 2021, 10, 16 | |
| NO20001846L (no) | Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer | |
| UA6752C2 (uk) | 4-(n-бензил) амінокарбоніл-1-метилпіридиній йодид-знеболюючий засіб з інтерфероногенними, протизапальними та жарознижуючими властивостями | |
| Gotoh | Gene therapy for prostate cancer | |
| AU630099B2 (en) | Non-reverting rna viruses | |
| AU630249B2 (en) | Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones | |
| MY117535A (en) | Hiv protease inhibitors | |
| DK0788355T3 (da) | Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0958371 Country of ref document: EP |